Clinical and Demographic Factors Associated With COVID-19, Severe COVID-19, and SARS-CoV-2 Infection in Adults

Key Points Question What clinical and demographic factors are associated with rates of COVID-19, severe COVID-19, and SARS-CoV-2 infection? Findings In this secondary analysis of 57 692 participants randomized to the placebo groups of 4 COVID-19 vaccine phase 3 efficacy trials, exposure risks, demographics (age and race), and evidence of previous infection had the strongest associations with study outcomes. Meaning These findings could inform public health policy pertaining to prioritization for vaccination and risk mitigation efforts.

[1]  J. Kublin,et al.  Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. , 2023, JAMA network open.

[2]  Xing Wu,et al.  B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates , 2022, Microbiology spectrum.

[3]  D. Follmann,et al.  Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial , 2022, Annals of Internal Medicine.

[4]  Benjamin Bowe,et al.  Long-term cardiovascular outcomes of COVID-19 , 2022, Nature Medicine.

[5]  N. Dreyer,et al.  EpidemiologiCal POpulatioN STudy of SARS-CoV-2 in Lake CounTy, Illinois (CONTACT): Methodology and Baseline Characteristics of a Community-Based Surveillance Study , 2022, Infectious Diseases and Therapy.

[6]  R. Grant,et al.  Accounting for Social Risk Does not Eliminate Race/Ethnic Disparities in COVID-19 Infection Among Insured Adults: a Cohort Study , 2022, Journal of General Internal Medicine.

[7]  S. Kahn,et al.  The Incidence of Diabetes Among 2,777,768 Veterans With and Without Recent SARS-CoV-2 Infection , 2022, Diabetes care.

[8]  L. Corey,et al.  Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico , 2021, medRxiv.

[9]  C. Mcevoy,et al.  Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine , 2021, The New England journal of medicine.

[10]  G. Tison,et al.  Predictors of incident SARS-CoV-2 infections in an international prospective cohort study , 2021, BMJ Open.

[11]  H. Ullum,et al.  Seroprevalence of SARS-CoV-2 antibodies and reduced risk of reinfection through 6 months: a Danish observational cohort study of 44 000 healthcare workers , 2021, Clinical Microbiology and Infection.

[12]  B. Zuckerman,et al.  A prospective cohort study on the intersectionality of obesity, chronic disease, social factors, and incident risk of COVID-19 in US low-income minority middle-age mothers , 2021, International Journal of Obesity.

[13]  Christine S. Smedley,et al.  Difference in mortality among individuals admitted to hospital with COVID-19 during the first and second waves in South Africa: a cohort study , 2021, The Lancet Global Health.

[14]  Derick R. Peterson,et al.  Incidence of Respiratory Syncytial Virus Infection among Hospitalized Adults, 2017-2020. , 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  S. Gómez-García,et al.  Risk Factors for SARS-CoV-2 Infection, Pneumonia, Intubation, and Death in Northeast Mexico , 2021, Frontiers in Public Health.

[16]  David A. Drew,et al.  Diet quality and risk and severity of COVID-19: a prospective cohort study , 2021, Gut.

[17]  A. Copas,et al.  Incidence of SARS-CoV-2 infection according to baseline antibody status in staff and residents of 100 long-term care facilities (VIVALDI): a prospective cohort study , 2021, The Lancet Healthy Longevity.

[18]  E. Zeggini,et al.  From first to second wave: follow-up of the prospective COVID-19 cohort (KoCo19) in Munich (Germany) , 2021, BMC Infectious Diseases.

[19]  H. Fennema,et al.  Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 , 2021, The New England journal of medicine.

[20]  P. Klenerman,et al.  SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) , 2021, The Lancet.

[21]  David A. Jolliffe,et al.  Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) , 2021, Thorax.

[22]  U. Fresán,et al.  Hypertension and Related Comorbidities as Potential Risk Factors for COVID-19 Hospitalization and Severity: A Prospective Population-Based Cohort Study , 2021, Journal of clinical medicine.

[23]  D. Weir,et al.  SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study , 2021, The Lancet Respiratory Medicine.

[24]  J. Zein,et al.  Association of Smoking and Cumulative Pack-Year Exposure With COVID-19 Outcomes in the Cleveland Clinic COVID-19 Registry. , 2021, JAMA internal medicine.

[25]  K. Telle,et al.  Factors associated with hospitalization, invasive mechanical ventilation treatment and death among all confirmed COVID-19 cases in Norway: Prospective cohort study , 2021, Scandinavian journal of public health.

[26]  J. Mascola,et al.  Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine , 2020, The New England journal of medicine.

[27]  G. Garber,et al.  Epidemiology, clinical characteristics, household transmission, and lethality of severe acute respiratory syndrome coronavirus-2 infection among healthcare workers in Ontario, Canada , 2020, PloS one.

[28]  D. Stuart,et al.  Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers , 2020, The New England journal of medicine.

[29]  E. Owusu-Dabo,et al.  Epidemiological profile of SARS-CoV-2 among selected regions in Ghana: A cross-sectional retrospective study , 2020, PloS one.

[30]  R. Clere-Jehl,et al.  Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020 , 2020, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[31]  K. Dua,et al.  Smoking and COVID-19: What we know so far , 2020, Respiratory Medicine.

[32]  J. Soriano,et al.  The impact of COVID-19 on patients with asthma , 2020, European Respiratory Journal.

[33]  F. Khamis,et al.  Characteristics of healthcare workers infected with COVID-19: A cross-sectional observational study , 2020, International Journal of Infectious Diseases.

[34]  Hongjie Yu,et al.  The disease burden of influenza beyond respiratory illness , 2020, Vaccine.

[35]  H. J. Kim,et al.  Effect of asthma and asthma medication on the prognosis of patients with COVID-19 , 2020, European Respiratory Journal.

[36]  C. Gale,et al.  Diabetes, glycaemic control, and risk of COVID-19 hospitalisation: Population-based, prospective cohort study , 2020, Metabolism.

[37]  J. Rainey,et al.  COVID-19 Among American Indian and Alaska Native Persons — 23 States, January 31–July 3, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[38]  P. Sullivan,et al.  Risk for COVID-19 infection and death among Latinos in the United States: examining heterogeneity in transmission dynamics , 2020, Annals of Epidemiology.

[39]  Angelo Carfì,et al.  Persistent Symptoms in Patients After Acute COVID-19. , 2020, JAMA.

[40]  C. Torp‐Pedersen,et al.  Association between male sex and outcomes of Coronavirus Disease 2019 (Covid‐19) – a Danish nationwide, register-based study , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[41]  Joanna Ellis,et al.  Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study , 2020, The Lancet Infectious Diseases.

[42]  John R. Mascola,et al.  A strategic approach to COVID-19 vaccine R&D , 2020, Science.

[43]  A. Shah,et al.  A clinical risk score to identify patients with COVID-19 at high risk of critical care admission or death: An observational cohort study , 2020, Journal of Infection.

[44]  Aaron van Dorn,et al.  COVID-19 exacerbating inequalities in the US , 2020, The Lancet.

[45]  Hemant Ishwaran,et al.  Standard errors and confidence intervals for variable importance in random forest regression, classification, and survival , 2018, Statistics in medicine.

[46]  D. Thompson,et al.  A case-control study of risk factors for death from 2009 pandemic influenza A(H1N1): is American Indian racial status an independent risk factor? , 2015, Epidemiology and Infection.

[47]  E. Walsh,et al.  Respiratory syncytial virus infection in elderly and high-risk adults. , 2005, The New England journal of medicine.

[48]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[49]  D. Thompson,et al.  Deaths related to 2009 pandemic influenza A (H1N1) among American Indian/Alaska Natives - 12 states, 2009. , 2009, MMWR. Morbidity and mortality weekly report.